Clinical Trials

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-03-18

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Multiple Myeloma

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT05438043 2026-03-16

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

52 enrolled

Multiple Myeloma

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

228 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

9 enrolled

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

130 enrolled

Multiple Myeloma, Neoplasms

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT04162210 2026-02-11

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01745640 2026-02-05

IFM2010-02

Phase 2 Completed

63 enrolled

Chromosome 17 deletion, Multiple Myeloma

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05020236 2026-02-02

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Multiple Myeloma, Recurrence

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

28 enrolled

Multiple Myeloma

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

90 enrolled

Multiple Myeloma, Recurrence

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

83 enrolled

304 enrolled 19 charts 1 FDA

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

117 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

200 enrolled

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

208 enrolled

Multiple Myeloma

NCT03590652 2025-10-21

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

23 enrolled

Multiple Myeloma, Neoplasms

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled

Multiple Myeloma, Recurrence

NCT03287908 2025-10-08

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

174 enrolled

Multiple Myeloma, Neoplasms

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT04302324 2025-10-01

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

9 enrolled

Multiple Myeloma

NCT03731832 2025-09-30

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

66 enrolled